年全球藥品支出將超過1萬億美元
Global pharmaceutical spending will surpassthe trillion dollar threshold in 2014, with high prices for innovativehepatitis C and cancer drugs in the US, a new study says. By 2018spending is expected to increase by another 30 percent.
一份新發布的研究表明，2014年，全球藥品支出將超過萬億美元，治療丙型肝炎和癌症的創新藥品爲高價藥。截至2018年，預計藥品支出費用將再提高三成。
With an increase of 7 percent over 2013,total spending on medicines will amount to $1.06trillion in 2014, says the report"The Global Use of Medicines: Outlook through2018" from the IMS Institute for Healthcare Informatics, releasedThursday.
據美國艾美仕醫療信息研究所週四發佈的名爲《全球用藥：展望2018》的報告，2013年的藥品費用支出提高了7個百分點，而2014年的藥品總支出將達1.06萬億美元。In the next few years, by 2018, theincrease to $1.3 trillion will be due to about $100 billion on hepatitis Cdrugs, the same sums spent on cancer treatment, and $78 billion on diabetescare.
未來數年時間內，截止2018年，支出將上升至1.3萬億美元。而1000億美元的丙型肝炎藥物支出及同等的癌症治療費用，還有780億美元的糖尿病治療費用都將是構成支出上升的因素。
The 30 percent increase is to be driven bymore specialty drug innovation, greater patient access to medicines and reducedimpact from patent expiry dates.
支出提升三成是由更專業的創新藥品，更多患者支付得起藥品以及放寬專利期限這些因素驅動的。The American share in the total drugspending is about one third. IMS experts estimate that in 2014 it will rise11.7 percent. The UShas particularly high prices, according to the report, but drug makers defendthis by citing the soaring cost of new medicine development.
美國的藥品支出費用約佔總量三分之一，據艾美仕研究所專家估計，2014年這個數值將上升11.7個百分點。據報道，美國的藥品支出費用價格特別高，但製藥商解釋說這是由於研製新藥的成本猛增。Spending on medicines in "pharmergingmarkets" will rise more than 50 percent over the next five years, ThePharma Letter said, citing IMS.
新聞網站PharmaLetter 援引艾美仕醫療信息研究所的話報道，“醫藥新興市場”在醫藥方面的支出費用將在未來5年上升百分之五十以上。With its goal of universal healthcaresystem coverage by 2020, Chinais expected to transform the medicine market, becoming the second largest afterthe the next five years, Chinaexpects per capita spending to grow by 70 percent.
爲實現2020年醫療保健制度覆蓋全民的目標，中國將改革藥品市場，這將使其成爲僅次於美國的第二大藥品支出市場。未來5年內，預計中國人均藥品支出將增長70%。
